A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)

September 16, 2026 updated by: Regeneron Pharmaceuticals

Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion Disease

This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD).

In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement.

ALN-6457 is designed to reduce the amount of prion protein made in the brain. ALN-6457 works by targeting the genetic "instructions" that cells use to produce this protein, with the goal of slowing or stopping disease progression.

This study is looking at:

  • What side effects ALN-6457 might cause
  • How well ALN-6457 works
  • What is the best dose of ALN-6457 for treating prion disease
  • How much ALN-6457 is in the blood and Cerebrospinal Fluid (CSF, fluid that surrounds the brain and spinal cord) at different times

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  1. Participant must meet all of the criteria under either:

    1. sporadic CJD as described in the protocol or
    2. genetic PrD, as described in the protocol
  2. Has a Body Mass Index (BMI) <35 kg/m2 (inclusive) at the screening visit

  3. Able to understand and complete trial-related questionnaires at screening

Key Exclusion Criteria:

  1. Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding prion disease) that, as assessed by the investigator, may confound the results of the trial or pose an additional risk to the participant during trial participation
  2. Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as described in the protocol
  3. Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
  4. An established allergy or intolerance to local anesthetics
  5. Current history of bleeding diatheses that would increase risk of bleeding upon LP
  6. Any malignancy that is progressing or requires active treatment, as described in the protocol
  7. Attempted suicide, suicidal ideation with a plan that required hospital admission and/or change in level of care within 12 months prior to screening

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose Escalation

Administered per the protocol

Other Names:
  • ALN-PRNP
Experimental: Cohort Expansion

Administered per the protocol

Other Names:
  • ALN-PRNP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Through Week 156
Through Week 156
Severity of TEAEs
Time Frame: Through Week 156
Through Week 156
Percentage change in concentration of Neurofilament Light chain (NfL) in plasma from baseline
Time Frame: Through Week 130
Through Week 130

Secondary Outcome Measures

Outcome Measure
Time Frame
Concentration of Prion Protein (PrP) in CSF
Time Frame: Through Week 130
Through Week 130
Change from baseline in concentration of PrP in CSF
Time Frame: Through Week 130
Through Week 130
Concentration of ALN-6457 and its major metabolites in plasma
Time Frame: Through Week 130
Through Week 130
Concentration of ALN-6457 and its major metabolites in CSF
Time Frame: Through Week 130
Through Week 130
Overall survival rate
Time Frame: At Week 52
At Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 23, 2026

Primary Completion (Estimated)

February 27, 2031

Study Completion (Estimated)

February 27, 2031

Study Registration Dates

First Submitted

September 16, 2026

First Submitted That Met QC Criteria

September 16, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 16, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD Sharing Time Frame

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD Sharing Access Criteria

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe